Compare SUNS & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | VRCA |
|---|---|---|
| Founded | 2023 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 88.0M |
| IPO Year | 2024 | 2018 |
| Metric | SUNS | VRCA |
|---|---|---|
| Price | $6.46 | $3.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $10.50 | ★ $13.83 |
| AVG Volume (30 Days) | ★ 102.1K | 44.6K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | ★ 18.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | $21,571,434.00 | ★ $35,577,000.00 |
| Revenue This Year | $89.71 | N/A |
| Revenue Next Year | $11.95 | $58.01 |
| P/E Ratio | $11.76 | ★ N/A |
| Revenue Growth | 102.96 | ★ 370.22 |
| 52 Week Low | $5.77 | $3.28 |
| 52 Week High | $10.45 | $9.82 |
| Indicator | SUNS | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 35.23 |
| Support Level | $5.77 | N/A |
| Resistance Level | $7.90 | $5.94 |
| Average True Range (ATR) | 0.29 | 0.35 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 45.58 | 19.48 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.